Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India

Epidermal growth factor receptor (EGFR) mutations are one of the best characterized driver mutations in primary lung adenocarcinomas (ADCAs), a subtype of non-small-cell lung cancer (NSCLC) [1 –3]. The mutations occur in a hotspot spanning exons 18–21 encoding the tyrosine kinase domain (TKD) of the EGFR gene, resulting in a mutant EGFR protein that is constitutively activated, leading to tumorigenesis. Small-molecule tyrosine kinase inhibitors (TKIs) competitively inhibit the binding of adenosine triphosphate to the intracellular kinase domain of the mutant EGFR protein, blocking its constitutive activation.

Source: Lung Cancer - September 11, 2020 Category: Cancer & Oncology Authors: Varsha Singh, Aruna Nambirajan, Prabhat Singh Mailk, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain Source Type: research